Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The current therapy of multiple sclerosis

D A Francis1

  • 1Department of Neurology, Queen Elizabeth Medical Centre, Birmingham, U.K.

Journal of Clinical Pharmacy and Therapeutics
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The gendered nature of South African teachers' discourse on sex education.

Health education research·2014
Same author

Glatiramer acetate (Copaxone).

International journal of clinical practice·2001
Same author

Association between the endogenous retrovirus HRES-1 and multiple sclerosis in the United Kingdom--evidence of genetically different disease subsets?

Disease markers·2001
Same author

CTLA4 in multiple sclerosis. Lack of genetic association in a European Caucasian population but evidence of interaction with HLA-DR2 among Shanghai Chinese.

Journal of the neurological sciences·2001
Same author

Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways.

The EMBO journal·2000
Same author

Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells.

Journal of virology·2000

Corticosteroid therapy is the primary treatment for multiple sclerosis exacerbations. Future multiple sclerosis treatments aim for disease prevention due to limited benefits from current immune-modulating agents.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Corticosteroid therapy is the current standard treatment for multiple sclerosis (MS) exacerbations.
  • Symptomatic treatments are used for chronic MS symptoms.
  • Existing immune-modulating agents offer insufficient clinical benefit for disease progression.

Purpose of the Study:

  • To review current multiple sclerosis treatment strategies.
  • To discuss the limitations of existing therapies.
  • To highlight the shift towards disease prevention in future MS treatment.

Main Methods:

  • Literature review of multiple sclerosis treatment modalities.
  • Analysis of the efficacy of corticosteroid therapy and immune-modulating agents.
  • Discussion of emerging trends in MS research.

Related Experiment Videos

Main Results:

  • High-dose intravenous methylprednisolone is the preferred treatment for acute MS exacerbations.
  • Symptomatic treatments manage chronic MS symptoms.
  • Immune-modulating agents have not demonstrated sufficient clinical benefit for routine use.

Conclusions:

  • Corticosteroid therapy remains the mainstay for managing multiple sclerosis.
  • Current immune-modulating therapies are not routinely used due to limited efficacy.
  • Future multiple sclerosis treatments are increasingly focused on disease prevention based on a better understanding of disease mechanisms.